CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR 工程化在实体瘤下一代免疫治疗中的变革
英文原题：Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
查看英文原题
Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）-T 细胞在临床治疗中具有巨大潜力。CAR-T 疗法已被批准用于治疗血液系统恶性肿瘤。然而，由于抗原丢失和突变、物理屏障以及免疫抑制性肿瘤微环境，其在实体瘤中的应用受到限制。为克服 CAR-T 面临的挑战，越来越多的努力投入到开发 CAR-T 以扩展其应用范围。多种受体被用于识别肿瘤相关抗原并缓解免疫抑制。新兴的共刺激信号被用于 CAR-T 激活。此外，其他免疫细胞如 NK 细胞和巨噬细胞已展现出递送 CAR 的潜力。因此，我们从三个方面，即胞外域、内源域和免疫细胞，收集并总结了 CAR 工程的最新进展，旨在为治疗实体瘤的下一代过继免疫治疗设计提供启发。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cells have enormous potentials for clinical therapies. The CAR-T therapy has been approved for treating hematological malignancies.
However, their application is limited in solid tumors owing to antigen loss and mutation, physical barriers, and an immunosuppressive tumor microenvironment. To overcome the challenges of CAR-T, increasing efforts are put into developing CAR-T to expand its applied ranges. Varied receptors are utilized for recognizing tumor-associated antigens and relieving immunosuppression. Emerging co-stimulatory signaling is employed for CAR-T activation.
Furthermore, other immune cells such as NK cells and macrophages have manifested potential for delivering CAR. Hence, we collected and summarized the last advancements of CAR engineering from three aspects, namely, the ectodomains, endogenous domains, and immune cells, aiming to inspire the design of next-generation adoptive immunotherapy for treating solid tumors.
论文信息
- 作者
- Yu T、Yu SK、Xiang Y、Lu KH、Sun M
- 第一作者单位
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.China
- 通讯作者单位
- Suzhou Cancer Center Core Laboratory, Suzhou Municipal Hospital, Gusu School, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 35903099 · DOI 10.3389/fimmu.2022.936496
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →